SurModics Stock Price, News & Analysis (NASDAQ:SRDX)

$46.55
+0.56 (+1.22 %)
(As of 09/23/2019 01:02 AM ET)
Today's Range
$45.79
Now: $46.55
$46.9950
50-Day Range
$42.68
MA: $45.18
$47.31
52-Week Range
$38.06
Now: $46.55
$74.97
Volume92,674 shs
Average Volume88,002 shs
Market Capitalization$627.96 million
P/E Ratio95.00
Dividend YieldN/A
Beta1.12
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$81.34 million
Cash Flow$0.9981 per share
Book Value$8.13 per share

Profitability

Net Income$-4,450,000.00

Miscellaneous

Employees338
Market Cap$627.96 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.


SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) issued its earnings results on Wednesday, July, 31st. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.10. The business earned $24.34 million during the quarter, compared to analysts' expectations of $22.76 million. SurModics had a return on equity of 4.87% and a net margin of 2.48%. View SurModics' Earnings History.

When is SurModics' next earnings date?

SurModics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for SurModics.

What guidance has SurModics issued on next quarter's earnings?

SurModics issued an update on its FY 2019 earnings guidance on Wednesday, August, 28th. The company provided earnings per share guidance of $0.69-0.77 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.43. The company issued revenue guidance of $97-99 million, compared to the consensus revenue estimate of $92.62 million.

What price target have analysts set for SRDX?

3 brokerages have issued 12-month price objectives for SurModics' stock. Their forecasts range from $64.00 to $75.00. On average, they expect SurModics' stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price. View Analyst Price Targets for SurModics.

What is the consensus analysts' recommendation for SurModics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics continues to gain from core Medical Devices unit which witnessed significant contribution from its SurVeil agreement with Abbott. Management anticipates this segment to see double-digit revenue growth in fiscal 2019. Strong sales of the company’s clinical components drove the IVD segment. Management is also optimistic about the ongoing TRANSCEND enrollment. Additionally, the company expects CE mark for SurVeil and other regulatory nods in the near future. The company’s FDA 510 (k) clearance for its Sublime guide sheath for radial access also buoys optimism. Meanwhile, lowered revenue guidance for fiscal 2019 and rising operating expenses remain concerns. the company’s drug-coated balloons face stiff competition in the niche space. Surmodics has underperformed the industry in a year's time." (7/23/2019)
  • 2. Needham & Company LLC analysts commented, "SRDX has embarked upon its whole-product solutions" strategy and has a number of medical devices in development or commercialization that it intends to sell through distribution partners. The potential revenue from these products varies widely; to use a baseball analogy, we think these product opportunities range from potential singles" (e.g. its 510(k) products) to potential home runs" (e.g. its drug-coated balloons or DCBs). Given the multiple moving parts of the SRDX story, we thought it would be worthwhile to conduct a “sum-of-the-parts” (SOTP) analysis. Our SOTP analysis implies that SRDX’s 2020E enterprise value should be ~$1.0B, or ~ $74 per SRDX share. Given this, we raise our price target to $74 from $69 and reiterate our Buy rating. Please contact us or your Needham sales person for our SRDX SOTP spreadsheet." (2/21/2019)

Has SurModics been receiving favorable news coverage?

News headlines about SRDX stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SurModics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for SurModics.

Are investors shorting SurModics?

SurModics saw a increase in short interest in August. As of August 31st, there was short interest totalling 851,000 shares, an increase of 25.9% from the July 31st total of 676,000 shares. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is currently 7.7 days. Currently, 6.5% of the shares of the company are sold short. View SurModics' Current Options Chain.

Who are some of SurModics' key competitors?

What other stocks do shareholders of SurModics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SurModics investors own include Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Intel (INTC), Adobe (ADBE), Exelixis (EXEL), Tandem Diabetes Care (TNDM), Micron Technology (MU), Neurocrine Biosciences (NBIX) and Supernus Pharmaceuticals (SUPN).

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 56)
  • Mr. Timothy J. Arens, Chief Financial Officer (Age 52)
  • Mr. Bryan K. Phillips, Sr. VP of Legal, HR & Information Technology, Gen. Counsel and Sec. (Age 48)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 53)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 59)

Who are SurModics' major shareholders?

SurModics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.27%), Renaissance Technologies LLC (7.79%), Trigran Investments Inc. (6.87%), Vanguard Group Inc. (6.67%), Janus Henderson Group PLC (2.41%) and Janus Henderson Group PLC (2.41%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Lisa Wipperman Heine, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which major investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Mackenzie Financial Corp, Mackenzie Financial Corp, AQR Capital Management LLC, GSA Capital Partners LLP, Acadian Asset Management LLC and Renaissance Technologies LLC. Company insiders that have sold SurModics company stock in the last year include Gary R Maharaj, Joseph J Stich and Lisa Wipperman Heine. View Insider Buying and Selling for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Trigran Investments Inc., Morgan Stanley, Marshall Wace LLP, SG Americas Securities LLC, Panagora Asset Management Inc., Vanguard Group Inc. and Zacks Investment Management. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $46.55.

How big of a company is SurModics?

SurModics has a market capitalization of $627.96 million and generates $81.34 million in revenue each year. The company earns $-4,450,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. SurModics employs 338 workers across the globe.View Additional Information About SurModics.

What is SurModics' official website?

The official website for SurModics is http://www.surmodics.com/.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (NASDAQ SRDX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  527
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel